Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ractigen Therapeutics has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners and 2 distinct art units. The concentration of 4 pending office actions within 2 distinct art units suggests a focused technical scope for the company's pharmaceutical filings.
SULLIVAN, STEPHANIE LAUREN is the busiest examiner, responsible for 2 busiest examiner pending office actions. This means this examiner is handling 2 of the company's 4 pending office actions. The remaining actions are split among the other 3 distinct examiners, indicating a concentrated workload for the lead examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, STEPHANIE LAUREN | 2 | 57.1% | +38.1% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275907 | Double-Stranded Nucleic Acid Molecule for Treating Proliferative Vitreoretinopathy and Use Thereof | SULLIVAN, STEPHANIE LAUREN | — |
| 18275900 | Chemically Modified Small Activating RNA | PERSONS, JENNA L | — |
| 18275895 | Multi-Valent Oligonucleotide Agent and Methods of Use Thereof | SULLIVAN, STEPHANIE LAUREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17419569 | OLIGOMERIC NUCLEIC ACID MOLECULE AND APPLICATION THEREOF | TRAN, CHRISTINA L | 73d overdue |
| 18275907 | Double-Stranded Nucleic Acid Molecule for Treating Proliferative Vitreoretinopathy and Use Thereof | SULLIVAN, STEPHANIE LAUREN | — |
| 18275900 | Chemically Modified Small Activating RNA | PERSONS, JENNA L | — |
| 18275895 | Multi-Valent Oligonucleotide Agent and Methods of Use Thereof | SULLIVAN, STEPHANIE LAUREN | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275907 | Double-Stranded Nucleic Acid Molecule for Treating Proliferative Vitreoretinopathy and Use Thereof | SULLIVAN, STEPHANIE LAUREN | 1635 | §101§103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18275900 | Chemically Modified Small Activating RNA | PERSONS, JENNA L | 1637 | §101§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18275895 | Multi-Valent Oligonucleotide Agent and Methods of Use Thereof | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Aug 04, 2023 |
| 17419569 | OLIGOMERIC NUCLEIC ACID MOLECULE AND APPLICATION THEREOF | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 73d overdue | Pending | Jun 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRactigen Therapeutics has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Stephanie Lauren Sullivan has the most, with 2 of Ractigen Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
